Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Gastroenterology Reports
Erschienen in: Current Gastroenterology Reports 12/2019

01.12.2019 | Gastroenterology in Geriatric Patients (S Chokhavatia, Section Editor)

Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem

verfasst von: Takeshi Kanno, Paul Moayyedi

Erschienen in: Current Gastroenterology Reports | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Proton pump inhibitors (PPIs) are one of the most prescribed drugs in the developed world and elderly patients are particularly likely to be prescribed acid suppression. There have been reports of many diseases being associated with PPI therapy and the elderly would be particular at risk of any harms these drugs may cause. This review therefore reviews the evidence of the risks and benefits of these drugs.

Recent Findings

PPIs are very effective at treating acid-related disorders. Recent randomized trials have suggested that the associations between PPI and various diseases are likely to be related to bias and residual confounding and these drugs appear to be safe apart from a possible increase risk of enteric infections.

Summary

PPIs should be used at the lowest dose and for the shortest duration possible. They are still relatively safe drugs but should only be prescribed for proven indications.
Literatur
1.
Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion. 1986;35(supple 1):42–55.PubMed
2.
Wormsley KG. Therapeutic achlorhydria and risk of gastric cancer. J Gastroenterol. 1989;24:585–96.
3.
Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2019;156(1):254–72.PubMed
4.
5.
Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–100.PubMed
6.
Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112:988–1013.PubMed
7.
8.
Jankowski JA, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400–8.PubMedPubMedCentral
9.
Rostom A, Dube C, Wells G, Tugwell P, Welch V, et al. Prevention of NSAID-induced gastroduodenal ulcer. Cochrane Database of Systematic Reviews. 2002;4:CD002296.
10.
Katz P, Gerson LB, Marcelo V. Guidelines for the diagnosis and management of gastro-esophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.PubMed
11.
Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–17.PubMed
12.
Halfdanarson OO, Pottegard A, Bjornsson ES, Lund SH, Ogmundsdottir MH, et al. Proton-pump inhibitors among adults: a nationwide drug-utlization study. Therapeutic Adv Gastroenterol. 2018;11:1–11.
13.
Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid suppressive drugs. JAMA. 2004;292:1955–60.PubMed
14.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.PubMed
15.
Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–95.PubMed
16.
Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patient with first time myocardial infarction: a nationwide propensity score matched analysis. BMJ. 2011;342:d2690.PubMedPubMedCentral
17.
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–46.PubMedPubMedCentral
18.
Gomm W, von Holt K, Thome F, Broich K, Maier W, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.PubMed
19.
Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e015735.PubMedPubMedCentral
20.
Ruigomez A, Wallander MA, Johansson S, et al. Natural history of gastroesophageal reflux disease diagnosed in UK general practice. Aliment Pharmacol Ther. 2004;20:751–60.PubMed
21.
Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res. 2001;18:1367–72.PubMed
22.
Williams B, Luckas M, Ellingham JH, Dain A, Wicks AC. Do young patients with dyspepsia need investigation? Lancet. 1988;2:1349–51.PubMed
23.
Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut. 2015;64:1049–57.PubMed
24.
Moayyedi P, Forman D, Braunholtz D, Crocombe W, Liptrott M, Axon ATR. The proportion of upper gastrointestinal symptoms in the community associated with Helicobacter pylori, lifestyle factors and non-steroidal anti-inflammatory drugs. American Journal of Gastroenterology. 2000;95:1448–55.
25.
Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic finding in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:830–7.PubMed
26.
Ford AC, Forman D, Bailey AG, Cook MB, Axon AT, Moayyedi P. Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol. 2007;102:957–65.PubMed
27.
Ford AC, Forman D, Reynolds PD, Cooper B, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol. 2005;162:454–60.PubMed
28.
Rubenstein JH, Mattek N, Eisen G. Age- and Gender-Specific Yeild of Barrett’s Esophagus by Endoscopy Indication. Gastrointestinal Endoscopy. 2010;71:21–7.PubMed
29.
Moayyedi P, Burch N, Akhtak-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett’s esophagus. Alimentary Pharmacology and Therapeutics. 2008;27:316–20.PubMed
30.
Lau JYW, Barkun A, Fan DM, Kuipers EJ, Yang Y-S, Chan FKL. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381:2033–43.PubMed
31.
32.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2019;157:403–12.PubMed
33.
Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–96.PubMed
34.
Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews. 2013;(5):Art. No.: CD002095. https://​doi.​org/​10.​1002/​14651858.​CD002095.​pub5.
35.
Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3:231–41.PubMedPubMedCentral
36.
37.
38.
Vaezi MF, Hicks DM, Abelson TI, Richter JE. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol. 2003;1:333–44.PubMed
39.
Milstein CF, Charbel S, Hicks MD, Abelson TI, Richter JE, Vaezi MF. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). Layrngoscope. 2005;115:2256–61.
40.
Lechien JR, Saussez S, Schindler A, Karkos PD, Hamdan AL, Harmegnies B, et al. Clinical outcomes of laryngopharyngeal reflux treatment: a systematic review and meta-analysis. Laryngoscope. 2019;129:1174–87.PubMed
41.
Vaezi MF, Richter JE, Stasney CR, Spiegel JR, Iannuzzi RA, Crawley JA, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116:254–60.PubMed
42.
Chang AB, Lasserson TJ, Gaffney J, Connor FL, Garske LA. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. The Cochrane Database of Systematic Reviews. 2011:CD004823.
43.
Chan WW, Chiou E, Obstein KL, Tignor AS, Whitlock TL. The efficacy of proton pump inhibitors for the treatment of asthma in adults: a meta-analysis. Arch Intern Med. 2011;171:620–9.PubMed
44.
Bo M, Gibello M, Brunetti E, Boietti E, Sappa M, et al. Prevalence and predictors of inappropriate prescribing according to the Screening Tool of Older People's Prescriptions and Screening Tool to Alert to Right Treatment version 2 criteria in older patients discharged from geriatric and internal medicine wards: A prospective observational multicenter study. Geriatr Gerontol Int. 2019;19:5–11.PubMed
45.
Schepisi R, Fusco S, Sganga F, Falcone B, Vetrano DL, et al. Inappropriate use of proton pump inhibitors in elderly patients discharged from acute care hospitals. J Nutr Health Aging. 2016;20:665–70.PubMed
46.
Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. Pharm Ther. 2015;40:256–76.
47.
Reilly JP. Safety profile of the proton-pump inhibitors. American journal of health-system pharmacy. 1999;56(23 Suppl 4):S11–7.PubMed
48.
van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, et al. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clinical pharmacokinetics. 2017;56:683–8.PubMedPubMedCentral
49.
Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. British journal of clinical pharmacology. 1991;32:569–72.PubMedPubMedCentral
50.
Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAj. 2009;180:713–8.PubMedPubMedCentral
51.
Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? American Journal of Gastroenterology. 2010;105:34–41.
52.
Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. New England Journal of Medicine. 2010;363:1909–17.
53.
Lewis JR, Barre D, Zhu K, Ivey KL, Lim EM, Hughes J, et al. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study. J Bone Miner Res. 2014;29:2489–97.PubMed
54.
Hussain S, Siddiqui AN, Habib A, Hussain MS, Najmi AK. Proton pump inhibitors' use and risk of hip fracture: a systematic review and meta-analysis. Rheumatology International. 2018;38:1999–2014.PubMed
55.
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183:310–9.PubMedPubMedCentral
56.
Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120–8.PubMed
57.
Batchelor R, Kumar R, Gilmartin-Thomas JFM, et al. Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmcol Ther. 2018;48:780–96.
58.
Gau JT, Yang YX, Chen R, Kao TC. Uses of proton pump inhibitors and hypomagnesemia. Pharmacoepidemiol Drug Saf. 2012;21:553–9.PubMed
59.
Bahtiri E, Islami H, Hoxha R, Gashi A, Thaci K, Karakulak C, et al. Proton pump inhibitor use for 12 months is not associated with changes in serum magnesium levels: a prospective open label comparative study. Turkish J Gastroenterol. 2017;28:104–9.
60.
Liao S, Gan L, Mei Z. Does the use of proton pump inhibitors increase the risk of hypomagnesemia: An updated systematic review and meta-analysis. Medicine. 2019;98:e15011.PubMedPubMedCentral
61.
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–42.PubMed
62.
Wod M, Hallas J, Andersen K, Garcia Rodriguez LA, Christensen K, Gaist D. Lack of Association Between Proton Pump Inhibitor Use and Cognitive Decline. Clin Gastroenterol Hepatol. 2018;16:681–9.PubMed
63.
Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review. J Gastroenterol Hepatol. 2017;32:1426–35.PubMed
64.
Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PloS one. 2012;7:e50836.PubMedPubMedCentral
65.
Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56.PubMed
66.
•• Vaezi M, Yang Y-X, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153:35–48 An excellent review article summarizing the evidence for harms of PPI therapy.PubMed
67.
Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9.PubMed
68.
Hvid-Jensen F, Nielsen RB, Pedersen L, Funch-Jensen P, Drewes AM, Larsen FB, et al. Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting. Clinical Epidemiology. 2013;5:493–9.PubMedPubMedCentral
69.
Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Alimentary Pharmacology & Therapeutics. 2015;41:1162–74.
70.
•• Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682–91 The largest randomized trial to show safety of PPIs with over 53,000 patients years of follow-up. This methodologically rigorous study suggests PPIs are not as harmful as observational studies suggest. PubMed
71.
Corely DA. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. Gastroenterology. 2019;157:604–7.
72.
Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152:706–15.PubMed
73.
Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ. The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncomPASS-A Cluster-Randomized Trial. Am J Gastroenterol. 2010;105:2341–6.PubMed
74.
75.
• Farrell V, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Canadian Family Physician. 2017;63:354–64 A useful guideline on how to reduce and stop patient’s PPI therapy. There is a helpful evidence-based algorithm that gives different approaches to reducing PPI intake.PubMedPubMedCentral
Metadaten
Titel
Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem
verfasst von
Takeshi Kanno
Paul Moayyedi
Publikationsdatum
01.12.2019
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 12/2019
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-019-0732-3

Weitere Artikel der Ausgabe 12/2019

Current Gastroenterology Reports 12/2019 Zur Ausgabe

Small Intestine (D Sachar, Section Editor)

Principles and Practice of Oral Rehydration

Pediatric Gastroenterology (S Orenstein and S Khan, Section Editors)

Pediatric Intestinal Pseudo-obstruction in the Era of Genetic Sequencing

GI Oncology (R Bresalier, Section Editor)

Gastrointestinal Motility Issues in Cancer Patients

Nutrition and Obesity (S McClave, Section Editor)

Controversy in Nutrition Recommendations for Short Bowel Syndrome: How Type of SBS Impacts Response

Stomach and Duodenum (J Pisegna and J Benhammou, Section Editors)

EUS-Guided Portal Venous Sampling of Circulating Tumor Cells

Esophagus (J Clarke and N Ahuja, Section Editors)

Tips for the Budding Esophagologist

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise